Targeting mutant p53 for cancer therapy: direct and indirect strategies

TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 protein oncogenic properties. The p53-targeted therapy approach began with the identification of compounds capable of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jiahao, Cao, Jiasheng, Topatana, Win, Juengpanich, Sarun, Li, Shijie, Zhang, Bin, Shen, Jiliang, Cai, Liuxin, Cai, Xiujun, Chen, Mingyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480024/
https://www.ncbi.nlm.nih.gov/pubmed/34583722
http://dx.doi.org/10.1186/s13045-021-01169-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480024/
https://www.ncbi.nlm.nih.gov/pubmed/34583722
http://dx.doi.org/10.1186/s13045-021-01169-0

Ejemplares similares